The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
ADHD Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.
The global ADHD Therapeutics market size is expected to reach US$ 23430 million by 2029, growing at a CAGR of 3.9% from 2023 to 2029. The market is mainly driven by the significant applications of ADHD Therapeutics in various end use industries. The expanding demands from the Specialty Clinics, Hospital Pharmacies, Retail Pharmacies and E-Commerce, are propelling ADHD Therapeutics market. Stimulants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-stimulants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Sale Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for ADHD Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global ADHD Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global ADHD Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, ADHD Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of ADHD Therapeutics covered in this report include Eli Lilly, Novartis, Takeda, Pfizer, GlaxoSmithKline, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical, Impax Laboratories and Johnson & Johnson, etc.
The global ADHD Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson & Johnson
UCB S.A.
Purdue Parma
Global ADHD Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global ADHD Therapeutics market, Segment by Type:
Stimulants
Non-stimulants
Global ADHD Therapeutics market, by Sale Channel
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of ADHD Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.
The global ADHD Therapeutics market size is expected to reach US$ 23430 million by 2029, growing at a CAGR of 3.9% from 2023 to 2029. The market is mainly driven by the significant applications of ADHD Therapeutics in various end use industries. The expanding demands from the Specialty Clinics, Hospital Pharmacies, Retail Pharmacies and E-Commerce, are propelling ADHD Therapeutics market. Stimulants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-stimulants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Sale Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for ADHD Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global ADHD Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global ADHD Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, ADHD Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of ADHD Therapeutics covered in this report include Eli Lilly, Novartis, Takeda, Pfizer, GlaxoSmithKline, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical, Impax Laboratories and Johnson & Johnson, etc.
The global ADHD Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson & Johnson
UCB S.A.
Purdue Parma
Global ADHD Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global ADHD Therapeutics market, Segment by Type:
Stimulants
Non-stimulants
Global ADHD Therapeutics market, by Sale Channel
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of ADHD Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of ADHD Therapeutics
1.1 ADHD Therapeutics Market Overview
1.1.1 ADHD Therapeutics Product Scope
1.1.2 ADHD Therapeutics Market Status and Outlook
1.2 Global ADHD Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global ADHD Therapeutics Market Size by Region (2018-2029)
1.4 Global ADHD Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global ADHD Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, ADHD Therapeutics Market Size (2018-2029)
1.6.1 North America ADHD Therapeutics Market Size (2018-2029)
1.6.2 Europe ADHD Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific ADHD Therapeutics Market Size (2018-2029)
1.6.4 Latin America ADHD Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa ADHD Therapeutics Market Size (2018-2029)
2 ADHD Therapeutics Market by Type
2.1 Introduction
2.1.1 Stimulants
2.1.2 Non-stimulants
2.2 Global ADHD Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global ADHD Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global ADHD Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America ADHD Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe ADHD Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific ADHD Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America ADHD Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa ADHD Therapeutics Revenue Breakdown by Type (2018-2029)
3 ADHD Therapeutics Market Overview by Sale Channel
3.1 Introduction
3.1.1 Specialty Clinics
3.1.2 Hospital Pharmacies
3.1.3 Retail Pharmacies
3.1.4 E-Commerce
3.2 Global ADHD Therapeutics Market Size by Sale Channel: 2018 VS 2022 VS 2029
3.2.1 Global ADHD Therapeutics Historic Market Size by Sale Channel (2018-2023)
3.2.2 Global ADHD Therapeutics Forecasted Market Size by Sale Channel (2024-2029)
3.3 Key Regions Market Size by Sale Channel
3.3.1 North America ADHD Therapeutics Revenue Breakdown by Sale Channel (2018-2029)
3.3.2 Europe ADHD Therapeutics Revenue Breakdown by Sale Channel (2018-2029)
3.3.3 Asia-Pacific ADHD Therapeutics Revenue Breakdown by Sale Channel (2018-2029)
3.3.4 Latin America ADHD Therapeutics Revenue Breakdown by Sale Channel (2018-2029)
3.3.5 Middle East and Africa ADHD Therapeutics Revenue Breakdown by Sale Channel (2018-2029)
4 ADHD Therapeutics Competition Analysis by Players
4.1 Global ADHD Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in ADHD Therapeutics as of 2022)
4.3 Date of Key Players Enter into ADHD Therapeutics Market
4.4 Global Top Players ADHD Therapeutics Headquarters and Area Served
4.5 Key Players ADHD Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 ADHD Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Eli Lilly
5.1.1 Eli Lilly Profile
5.1.2 Eli Lilly Main Business
5.1.3 Eli Lilly ADHD Therapeutics Products, Services and Solutions
5.1.4 Eli Lilly ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Eli Lilly Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis ADHD Therapeutics Products, Services and Solutions
5.2.4 Novartis ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Takeda
5.3.1 Takeda Profile
5.3.2 Takeda Main Business
5.3.3 Takeda ADHD Therapeutics Products, Services and Solutions
5.3.4 Takeda ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer ADHD Therapeutics Products, Services and Solutions
5.4.4 Pfizer ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business
5.5.3 GlaxoSmithKline ADHD Therapeutics Products, Services and Solutions
5.5.4 GlaxoSmithKline ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 GlaxoSmithKline Recent Developments
5.6 Mallinckrodt Pharmaceuticals
5.6.1 Mallinckrodt Pharmaceuticals Profile
5.6.2 Mallinckrodt Pharmaceuticals Main Business
5.6.3 Mallinckrodt Pharmaceuticals ADHD Therapeutics Products, Services and Solutions
5.6.4 Mallinckrodt Pharmaceuticals ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Mallinckrodt Pharmaceuticals Recent Developments
5.7 Hisamitsu Pharmaceutical
5.7.1 Hisamitsu Pharmaceutical Profile
5.7.2 Hisamitsu Pharmaceutical Main Business
5.7.3 Hisamitsu Pharmaceutical ADHD Therapeutics Products, Services and Solutions
5.7.4 Hisamitsu Pharmaceutical ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Hisamitsu Pharmaceutical Recent Developments
5.8 Impax Laboratories
5.8.1 Impax Laboratories Profile
5.8.2 Impax Laboratories Main Business
5.8.3 Impax Laboratories ADHD Therapeutics Products, Services and Solutions
5.8.4 Impax Laboratories ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Impax Laboratories Recent Developments
5.9 Johnson & Johnson
5.9.1 Johnson & Johnson Profile
5.9.2 Johnson & Johnson Main Business
5.9.3 Johnson & Johnson ADHD Therapeutics Products, Services and Solutions
5.9.4 Johnson & Johnson ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Johnson & Johnson Recent Developments
5.10 UCB S.A.
5.10.1 UCB S.A. Profile
5.10.2 UCB S.A. Main Business
5.10.3 UCB S.A. ADHD Therapeutics Products, Services and Solutions
5.10.4 UCB S.A. ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 UCB S.A. Recent Developments
5.11 Purdue Parma
5.11.1 Purdue Parma Profile
5.11.2 Purdue Parma Main Business
5.11.3 Purdue Parma ADHD Therapeutics Products, Services and Solutions
5.11.4 Purdue Parma ADHD Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Purdue Parma Recent Developments
6 North America
6.1 North America ADHD Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe ADHD Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific ADHD Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America ADHD Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa ADHD Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 ADHD Therapeutics Market Dynamics
11.1 ADHD Therapeutics Industry Trends
11.2 ADHD Therapeutics Market Drivers
11.3 ADHD Therapeutics Market Challenges
11.4 ADHD Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
